UK markets closed
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • FTSE 250

    22,336.10
    +266.79 (+1.21%)
     
  • AIM

    1,236.38
    +11.54 (+0.94%)
     
  • GBP/EUR

    1.1612
    -0.0014 (-0.12%)
     
  • GBP/USD

    1.4089
    +0.0037 (+0.26%)
     
  • BTC-GBP

    35,912.10
    +1,528.43 (+4.45%)
     
  • CMC Crypto 200

    1,419.12
    +60.56 (+4.46%)
     
  • S&P 500

    4,173.12
    +60.62 (+1.47%)
     
  • DOW

    34,386.94
    +365.49 (+1.07%)
     
  • CRUDE OIL

    65.22
    +1.40 (+2.19%)
     
  • GOLD FUTURES

    1,838.40
    +14.40 (+0.79%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     
  • HANG SENG

    28,027.57
    +308.90 (+1.11%)
     
  • DAX

    15,416.64
    +216.96 (+1.43%)
     
  • CAC 40

    6,385.14
    +96.81 (+1.54%)
     

Virus tests save Roche as drug sales slide

Virus tests are proving to be a saving grace for Roche.

The Swiss pharmaceuticals giant saw drug sales slide in the first quarter.

They were down 9% over the period.

Revenues were hit as the global health crisis limited visits to hospitals and health centers.

But it was a different story on virus testing.

Sales at the firm's diagnostics division leapt by 55%.

That almost offset the slump in shipments of drugs.

Overall, Roche first-quarter sales dipped 1% to 14.9 billion swiss francs - or about 16.3 billion dollars.

Last year Chief Executive Severin Schwan was confident that drug sales would soon normalise.

But now he says the lingering crisis continues to have a negative impact.

Even so, the company still expects current-year sales growth in the low- to mid-single-digit range.

Core earnings are seen rising at a similar rate.

Roche shares rose over 1.5% in early trade on Wednesday (April 21).